References:
- Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human
benign prostatic hyperplasia with age. J Urol 1984; 132:
474-479.
- Abrams P, Cardozo L, Fall M, Griffiths D, et al. The standardisation
of terminology of lower urinary tract function: report from the
Standardisation Sub-committee of the International Continence Society.Neurourol Urodynam 2002; 21: 167-178.
- Kupelian V, Wei JT, O’Leary MP, et al. Prevalence of lower urinary
tract symptoms and effect on quality of life in a racially and
ethnically diverse random sample: the Boston Area Community Health
(BACH) Survey. Arch Intern Med 2006; 166: 2381-2387.
- Calais Da Silva F, Marquis P, Deschaseaux P et al. Relative importance
of sexuality and quality of life in patients with prostatic symptoms.Eur Urol 1997; 31: 272–280.
- Emberton M, Martorana G. BPH: social impact and patient’s perspective.
Eur Urol Suppl. 2006; 5: 991–996.
- Hong SJ, Rayford W, Valiquette L, Emberton M. The importance of
patient perception in the clinical assessment of benign prostatic
hyperplasia and its management. BJU Int 2005; 95: 15–19.
- Gravas S, Cornu JN, Gacci M, et al. Management of Non-neurogenic Male
LUTS.https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts
- Gormley EA, Lightner DJ, Burgio
KL, et al. Diagnosis and treatment of overactive bladder
(non-neurogenic) in adults: AUA/SUFU guideline. J Urol 2012;
188 (6 Suppl): 2455–2463.
- Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z.
Tolterodine and tamsulosin for treatment of men with lower urinary
tract symptoms and overactive bladder: a randomized controlled trial.JAMA 2006; 296: 2319–2328.
- Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W. Safety and
tolerability of solifenacin add-on therapy to alpha-blocker treated
men with residual urgency and frequency. J Urol 2009; 182:
2825–2830.
- Matsuo T, Miyata Y, Kakoki K, et al. The efficacy of mirabegron
additional therapy for lower urinary tract symptoms after treatment
with α1-adrenergic receptor blocker monotherapy: prospective analysis
of elderly men. BMC Urol 2016; 16: 45.
- Gacci M, Sebastianelli A, Spatafora P, et al. Best practice in the
management of storage symptoms in male lower urinary tract symptoms: a
review of the evidence base. Ther Adv Urol 2017; 10: 79–92.
- Borkowski T, Golabek T, Chlosta PL, Borkowski A. Evaluation and
management of male lower urinary tract symptoms: treatment patterns
and guidelines in a correlation study among Polish urology
consultants. Arch Med Sci 2015; 11: 1340–1351.
- Barry MJ, Fowler FJ Jr, O’Leary MP et al. The American Urological
Association symptom index for benign prostatic hyperplasia. The
Measurement Committee of the American Urological Association. J
Urol 1992; 148: 1549–1557.
- Prajsner A, Chudek J, Szybalska A, Piotrowicz K, Zejda J, Więcek A.
,Socioeconomic profile of elderly Polish men treated for benign
prostate hyperplasia: Results of the population-based PolSenior study.Eur Geriatr Med 2015; 6: 53–57.
- Vouri SM, Strope SA, Olsen MA, Xian H, Schootman M. Antimuscarinic Use
in Men Treated With Bladder Outlet Obstruction Medication Therapy.Urology 2018; 122: 76–82.
- Errando-Smet C, Müller-Arteaga C, Hernández M, Roset M. Diagnosis and
treatment of male patients with lower urinary tract symptoms in Spain
- The MERCURY Study. Do urologists follow the recommendations of the
European guidelines? Actas Urol Esp 2018; 42: 323–330.
- Azzouni F, Mohler J. Role of 5α-reductase inhibitors in prostate
cancer prevention and treatment. Urology. 2012 ; 79:
1197–1205.
- Azzouni F, Mohler J. Role of 5α-reductase inhibitors in benign
prostatic diseases. Prostate Cancer Prostatic Dis 2012; 15: 222–230.
- Barlik M, Jacyków D, Lewandowska B, Mirosław J, Siwiak K, Wągrowska U.
Household budget survey in 2018. Statistics Poland.https://stat.gov.pl/obszary-tematyczne/warunki-zycia/dochody-wydatki-i-warunki-zycia-ludnosci/budzety-gospodarstw-domowych-w-2018-r-,9,13.html(published Sept 27 2019).
Table 1: The characteristics of the analysed group of men with prostatic
enlargement, pharmacologically treated for BPH.